现代医药卫生2024，Vol.40Issue(17)：2888-2892,2899,6.DOI:10.3969/j.issn.1009-5519.2024.17.002
慢性髓性白血病伴附加染色体异常疗效及预后的相关性分析
Correlation analysis of therapeutic effect and prognosis of chronic myeloid leukemia with additional chromosomal abnormalities
摘要
Abstract
Objective To explore the correlation between the diagnosis,treatment,progression and prognosis of chronic myeloid leukemia(CML)in chronic phase(CML-CP)patients with additional chromo-somal abnormalities(ACAs)at the initial diagnosis.Methods The clinical data of 92 patients with newly di-agnosed CML-CP admitted to the hospital from January 1,2016 to December 31,2022 were retrospectively an-alyzed.The clinical and genetic characteristics were analyzed.Kaplan Meier method was used to analyze the differences in survival distribution of CML-CP patients with or without ACAs,and to explore the correlation between CML-CP patients with ACAs and disease diagnosis,treatment,and prognosis.Results BCR-ABL1 fusion gene was detected in the initial bone marrow images of 92 CML-CP patients(100%positive rate),with 82 cases(89.13%)in the pure t(9;22)group and 10 cases(10.87%)in the ACAs group.The survival time of CML-CP patients was 78.49-87.64 months,with a median of 83.06 months.Compared with simple t(9;22),the onset age and overall survival time of ACAs patients were lower,and they had a higher risk of infection,and the differences were statistically significant(P<0.05).ACAs were independent risk factors for poor prognosis in CML-CP patients.Conclusion ACAs may be one of the factors leading to the progression and poor prognosis of CML.关键词
慢性髓性白血病/附加染色体异常/治疗结果/预后/相关性研究Key words
Chronic myeloid leukemia/Additional chromosomal abnormalities/Treatment out-come/Prognosis/Correlational study分类
医药卫生引用本文复制引用
闫利,安福润,杨冬冬,翟志敏..慢性髓性白血病伴附加染色体异常疗效及预后的相关性分析[J].现代医药卫生,2024,40(17):2888-2892,2899,6.基金项目
国家自然科学基金项目(81670179) （81670179）
安徽省科技重大专项基金项目(201903a07020030). （201903a07020030）
